shares of adc therapeutics sa rose after the biotechnology company said the european commission granted a conditional marketing authorization for the use of zynlonta to treat relapsed or refractory diffuse large bcell lymphoma shares of adc therapeutics rose more than 24 to 396 in premarket trading the stock is down about 84 this year the european commissions decision is valid in all european union member states iceland norway and liechtenstein the company said the conditional marketing authorization and continued approval may be contingent upon verification in a confirmatory trial earlier this year adc therapeutics said it struck an exclusivelicense deal with swedish orphan biovitrum ab also called sobi to develop and commercialize zynlonta for all hematologic and solid tumor indications in europe and certain other territories under the terms of the deal the european commission decision triggers a 50 million milestone payment from sobi to adc therapeutics the drug has been approved by the us food and drug administration write to will feuer at willfeuerwsjcom